Nicox S.A. to co promote Latanoprostene bunod in US with Bausch + Lomb for Glaucoma + Ocular Hypertension.
Nicox S.A. the international ophthalmic company, announced it has notified Bausch + Lomb (B+L), a division of Valeant Pharmaceuticals International, Inc., of its decision to exercise the option to co-promote latanoprostene bunod in the United States.
Latanoprostene bunod is a nitric oxide (NO)-donating prostaglandin F2-alpha analog in phase III clinical development for the potential treatment of Glaucoma and Ocular Hypertension which was licensed by Nicox to B+L in 2010. B+L�s phase III clinical program includes two studies, APOLLO and LUNAR, which are pivotal for registration in the US. Valeant recently said that it expects to receive top-line efficacy results from the first of these phase III studies in the third quarter of 2014, and from the second of these studies in the fourth quarter of 2014. Valeant also said latanoprostene bunod could be launched in the US in 2016, pending approval from the FDA.
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
The Menarini Group and Radius Health announced positive topline results from the phase III EMERALD study evaluating RAD 1901 (elacestrant) as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC).
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.